Patient-Preferred Therapy in ALK+ Lung Cancer
Dr. Mark Kris underscores the advantages of crizotinib and other ALK-targeted therapies for ALK+ lung cancer and looks askance at recent data on toxicity levels and cost-effectiveness of testing.
Source: Medscape Pathology and Laboratory Medicine Podcast - Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
More News: Cancer | Cancer & Oncology | Laboratory Medicine | Lung Cancer | Pathology | Podcasts | Toxicology